Urinary Sex Steroid Metabolites: Which Tests to Order Alongside

Import from '@/components/mdx'

What Urinary Sex Steroid Metabolites Actually Measure

Urinary sex steroid metabolites do not simply mirror the estrogen level in your blood. They map the downstream chemistry: which enzymes your liver and gut are using to break estrogen apart, and which end-products you are excreting.

The two most clinically discussed pathways split at the liver. CYP1A1 and CYP1A2 enzymes push estrone toward 2-hydroxyestrone (2-OHE1), sometimes called the "weaker" or "protective" metabolite. CYP1B1 pushes estrone toward 16α-hydroxyestrone (16α-OHE1), a metabolite with stronger estrogenic activity at the receptor level. A third pathway produces 4-hydroxyestrone (4-OHE1), which can generate reactive quinones that form DNA adducts, though 4-OHE1 is measured in specialized research panels and is not routinely available from most commercial labs.

The 2-OH to 16-OH Ratio: What the Research Actually Shows

The ratio of 2-OHE1 to 16α-OHE1 became clinically popular after the ORDET cohort study reported that women with a higher 2-OH:16-OH ratio had a lower risk of breast cancer. Subsequent work, including a pooled analysis of eight prospective studies published in Cancer Epidemiology, Biomarkers and Prevention, found the association was not statistically significant across all populations once confounders were controlled.

That nuance matters for your clinical decisions. The ratio is a useful physiological marker, not a validated screening tool for breast cancer. Ordering it in the right clinical context, alongside the right companion tests, is what makes the result actionable.

How CYP and COMT Genetics Influence Your Results

Two genetic variants change how you metabolize estrogen regardless of your lifestyle.

• CYP1B1 Val158Met (rs1056836): The Val/Val genotype produces more 16-OHE1 relative to 2-OHE1. Women carrying two Val alleles have measurably higher 16-OHE1 excretion in several case-control studies.
• COMT Val158Met (rs4680): COMT methylates 2-OHE1 into the benign 2-methoxyestrone. The Met/Met (slow) genotype leads to lower 2-methoxyestrone and higher circulating 2-catechols, which may increase oxidative stress rather than clearance.

Adding pharmacogenomic testing for these two variants can explain a ratio that looks poor despite good diet and low body weight. Most insurance plans do not cover this testing, and the clinical utility is still being studied. State that to your patient directly.

Normal Ranges and Life-Stage Interpretation

No single "normal" applies across all life stages. The reference interval you use matters as much as the result itself.

Reproductive Years (Ages 18 to 45, Cycling)

In premenopausal women with regular cycles, urinary 2-OHE1 ranges from approximately 1.0 to 9.0 ng/mg creatinine and 16α-OHE1 from 0.5 to 5.0 ng/mg creatinine, though exact reference ranges differ by lab methodology and collection type. A 2-OH:16-OH ratio above 2.0 is considered favorable by most functional-medicine references, while some integrative oncology panels flag ratios below 1.5 for follow-up. Collect the urine on day 19 to 21 of a 28-day cycle when estrogen metabolite excretion is most stable; mid-cycle LH surges transiently alter CYP1A1 activity.

Perimenopause (Typically Ages 45 to 55)

Perimenopause brings erratic estradiol production and rising FSH. Urinary metabolite patterns become harder to interpret because cycle length varies and anovulatory cycles produce a different estrogen-metabolite profile. The Menopause Society (formerly NAMS) does not endorse urinary estrogen metabolite testing as a standard perimenopausal assessment, preferring symptom-based and serum hormone evaluation. The test may still add value in women with a personal or family history of hormone-sensitive cancers who want additional context, but interpret results cautiously in the context of highly variable cycle-phase timing.

Post-Menopause

After menopause, ovarian estrogen production falls dramatically and adrenal androgen conversion becomes the dominant estrogen source. 16-OHE1 excretion drops substantially post-menopause, which means a "good" ratio can look impressive simply because total estrogen production is low, not because metabolism is favorable. For post-menopausal women on menopausal hormone therapy (MHT), the type of estrogen given (oral vs. Transdermal) directly shifts the metabolite pattern: oral estradiol undergoes first-pass hepatic metabolism that increases 2-OHE1 relative to transdermal routes. Add that context to any interpretation.

PCOS

Women with PCOS often have elevated androgens (testosterone, DHEA-S) and insulin resistance, both of which alter CYP enzyme activity. Hyperinsulinemia downregulates hepatic CYP1A2, potentially shifting the ratio toward 16-OHE1 independent of body weight. Order fasting insulin and HOMA-IR alongside the metabolite panel in any woman with PCOS. Correcting insulin resistance with metformin or inositol may shift the ratio favorably, though direct trial data on this specific endpoint in PCOS are thin.

Which Tests to Order Alongside Urinary Sex Steroid Metabolites

The table below organizes companion labs into three tiers based on clinical priority. Use this framework to build a complete hormonal and metabolic panel rather than ordering the metabolite test in isolation.

Tier 1: Essential Companion Labs (Order Every Time)

These labs provide the physiological context without which the metabolite result is nearly uninterpretable.

| Lab | Why it pairs with metabolite testing | Timing notes | |---|---|---| | Serum estradiol (E2) | Anchors total estrogen production; a low ratio on low total E2 means something different than low ratio on high E2 | Day 3 or day 19-21 of cycle | | FSH and LH | Distinguishes ovulatory from anovulatory cycles; confirms menopausal status | Day 2-3 of cycle, or any day if post-menopausal | | SHBG | Modulates free estrogen available for hepatic metabolism; elevated SHBG reduces bioavailable E2 | Any time of day | | Fasting insulin and glucose | Insulin resistance shifts CYP enzyme activity toward more 16-OHE1 | 8-12 hour fast | | TSH with free T4 | Hypothyroidism reduces CYP1A2 activity and impairs phase II glucuronidation | Any time of day |

Tier 2: Condition-Specific Add-Ons

Add these based on clinical presentation and history.

For women with PCOS or androgenic symptoms:

• Total and free testosterone
• DHEA-S
• HOMA-IR (calculated from fasting insulin and glucose)
• Androstenedione if adrenal source suspected

For women with a personal or family history of hormone-sensitive breast cancer:

• 4-OHE1 (via specialized labs such as Genova Diagnostics or ZRT laboratory)
• 2-methoxyestrone
• COMT Val158Met genotype
• CYP1B1 Val158Met genotype

For women on menopausal hormone therapy or hormonal contraception:

• Serum progesterone or urinary pregnanediol-glucuronide if on micronized progesterone
• Liver enzymes (ALT, AST, GGT) because hepatic function directly affects phase I and II estrogen metabolism

Tier 3: Lifestyle and Nutritional Markers

These labs explain why a ratio is low and point toward modifiable causes.

• Magnesium (RBC, not serum): Magnesium is a cofactor for COMT. Low intracellular magnesium impairs methylation of 2-catechol estrogens.
• Methylmalonic acid and homocysteine: Elevated values indicate B12 or folate insufficiency, which undermines COMT-mediated methylation.
• Urinary indole-3-carbinol metabolites (optional): Cruciferous vegetable intake induces CYP1A1 and shifts production toward 2-OHE1. Some specialty labs offer this marker.
• Omega-3 index: Higher omega-3 intake correlates with more favorable 2-OH:16-OH ratios in observational data.

How to Raise or Lower Specific Metabolites

Correcting a metabolite ratio requires understanding which pathway is dysregulated. Do not treat the ratio as a binary problem.

Raising 2-OHE1 (Shifting Toward the Protective Pathway)

• Indole-3-carbinol (I3C) and diindolylmethane (DIM): The most studied dietary interventions. A randomized trial by Bradlow et al. Showed that I3C supplementation at 400 mg/day for 3 months significantly increased urinary 2-OHE1 and improved the 2-OH:16-OH ratio in premenopausal women. DIM is the bioactive condensation product of I3C and may be better tolerated.
• High-fiber diet: Dietary fiber supports gut microbiome diversity and reduces beta-glucuronidase activity, allowing better estrogen clearance rather than reabsorption of conjugated estrogens. The estrobolome, the subset of gut bacteria that metabolize estrogens, directly modifies urinary estrogen metabolite profiles.
• Aerobic exercise: At least 150 minutes per week of moderate-intensity exercise is associated with higher 2-OH:16-OH ratios in observational cohorts, likely through upregulation of CYP1A1 in adipose tissue.
• Weight management: Adipose tissue is rich in aromatase and CYP1B1, so excess fat mass increases 16-OHE1 production. A 5 to 10 percent body weight reduction in overweight women may meaningfully shift the ratio.

Lowering 16α-OHE1

Lowering 16-OHE1 is partly achieved by the same strategies above. Two additional considerations apply.

• Alcohol reduction: Alcohol induces CYP1B1 and inhibits CYP1A2, a double shift toward 16-OHE1. Even moderate alcohol consumption of one drink per day raises breast cancer risk by approximately 7 to 10 percent, an effect that may be partly mediated through this metabolite shift.
• Reducing exogenous estrogen load: High-dose oral contraceptives and non-bioidentical estrogens after menopause increase overall hepatic estrogen flux. Discuss the route and dose of any hormone therapy with your clinician before attributing a high 16-OHE1 solely to genetics.

Supporting Phase II Methylation and Glucuronidation

Even a favorable 2-OHE1 level is not protective if it accumulates as a reactive catechol rather than being methylated to 2-methoxyestrone or glucuronidated for urinary excretion.

Support methylation with:

• Methylfolate (400 to 800 mcg daily for most women; dose varies with MTHFR genotype)
• Methylcobalamin (B12)
• Magnesium glycinate or malate (200 to 400 mg elemental magnesium daily)

Support glucuronidation with:

• Calcium-D-glucarate (1,000 to 1,500 mg daily in divided doses; inhibits beta-glucuronidase)
• Avoidance of alcohol, which competes with glucuronidation enzymes

What a High or Low Result Actually Means Clinically

High 16α-OHE1 or Low 2-OH:16-OH Ratio

A low ratio (below 1.5 in most lab references) may reflect:

• Obesity or central adiposity
• Alcohol use
• Hypothyroidism
• CYP1B1 Val/Val genotype
• Estrogen-dominant states (late reproductive years, anovulatory PCOS)
• Perimenopause with fluctuating, sometimes supraphysiologic E2 levels

The Endocrine Society's clinical practice guidelines on estrogen-related conditions do not specify a target metabolite ratio as a treatment endpoint. The AACE does not currently recommend routine urinary estrogen metabolite testing in its obesity or PCOS guidelines. That does not make the test worthless. It means the result should inform conversation, not drive isolated treatment.

Low 16α-OHE1 With Low Total Estrogen

This pattern appears in post-menopausal women with low total estrogen output and in female athletes with hypothalamic amenorrhea. Here a "good" ratio may obscure the real problem: insufficient estrogen exposure for bone protection, cardiovascular function, and cognitive health. Bone mineral density loss begins within the first 1 to 2 years after menopause and averages 1 to 2 percent per year in the early post-menopausal period. Treating the ratio while ignoring total estrogen insufficiency is a clinical error.

Pregnancy and Lactation Considerations

Urinary sex steroid metabolite testing is not clinically indicated during pregnancy. Here is why.

16α-hydroxyestrone rises dramatically in normal pregnancy because placental estriol synthesis generates large amounts of 16-hydroxylated precursors. A ratio that looks alarming in a non-pregnant reference range is physiologically normal in pregnancy. Testing in this context produces misleading results and unnecessary anxiety.

During lactation, estrogen production remains suppressed due to prolactin. Urinary estrogen metabolite levels are low across all pathways. The ratio may appear favorable but reflects suppressed production rather than healthy metabolism. Retesting 3 to 6 months after weaning gives a more clinically meaningful baseline.

Women trying to conceive who are undergoing metabolite testing should collect the sample on day 19 to 21 of the cycle, confirm ovulation with a serum progesterone above 3 ng/mL on the same day, and repeat the test in the follicular phase if cycle length is irregular. A single-time-point metabolite test during an anovulatory cycle gives a distorted picture.

No drug used to support estrogen detox pathways (I3C, DIM, calcium-D-glucarate) has adequate human safety data in pregnancy. Discontinue all of these supplements when pregnancy is confirmed or when actively trying to conceive without close clinical supervision.

Who Should Order This Test and Who Should Not

Women Who May Benefit

• Premenopausal women with a first-degree relative diagnosed with estrogen-receptor-positive breast cancer who want detailed estrogen metabolism profiling as part of a risk-informed lifestyle plan
• Women with PCOS and elevated estrogen-to-progesterone ratios not fully explained by cycle status
• Post-menopausal women on oral MHT who want to understand their hepatic estrogen metabolism before deciding whether to switch to transdermal delivery
• Women with unexplained symptoms of estrogen excess (breast tenderness, heavy bleeding, bloating, fibroid growth) despite normal serum E2

Women for Whom This Test Adds Little

• Healthy cycling women with no hormonal symptoms and no family history of hormone-sensitive cancer. The result rarely changes management.
• Women currently pregnant or within 3 months postpartum.
• Women with active eating disorders, hypothalamic amenorrhea, or premature ovarian insufficiency where the priority is restoring total estrogen, not refining the metabolite ratio.
• Women who will not or cannot implement the dietary and lifestyle changes that move the ratio. A result without an actionable plan is an anxiety generator.

As WomanRx medical reviewer Maya Okafor, MD, puts it: "I order urinary estrogen metabolites maybe once in fifteen patients who ask about it. The ratio is meaningful context, not a number to chase. I want to know that insulin is controlled, the thyroid is working, and the diet has cruciferous vegetables before I even look at whether DIM is indicated."

Collecting the Sample Correctly

Collection errors are the most common reason for uninterpretable results.

First-morning void (spot urine):

• Collect on day 19 to 21 of a typical 28-day cycle.
• Confirm that creatinine-adjusted values are available from your lab (required to correct for hydration status).
• Avoid alcohol for 72 hours before collection.
• Avoid I3C or DIM supplements for 7 days before collection.

24-hour urine:

• More complete but logistically demanding.
• Useful when a spot urine gives borderline results or when total estrogen load (not just the ratio) is clinically relevant.

DUTCH dried-urine test:

• Collects four timed urine samples on absorbent cards.
• Measures phase I metabolites (2-OHE1, 4-OHE1, 16-OHE1) and phase II downstream products (2-methoxyestrone, 2-methoxyestradiol).
• DUTCH test methodology has been validated against 24-hour urine in a published comparison study, with good correlation for most estrogen metabolites.
• Not yet endorsed by ACOG or the Endocrine Society for routine clinical use.

Evidence Gaps and Honest Limitations

Women have been substantially underrepresented in the trials that established the clinical relevance of the 2-OH:16-OH ratio. Most foundational work used small case-control designs, relied on a single urine collection, and did not control for menstrual cycle phase.

A 2012 systematic review in Cancer Epidemiology, Biomarkers and Prevention examined eight prospective studies totaling more than 6,000 women and found no statistically significant overall association between the 2-OH:16-OH ratio and breast cancer risk. Subgroup analyses suggested possible associations in post-menopausal women or those with higher BMI, but these were hypothesis-generating, not definitive.

No randomized controlled trial has tested whether improving the ratio by any intervention reduces incident breast cancer, endometrial cancer, or recurrence. Until that trial exists, using the metabolite ratio as a treatment target rather than a contextual data point goes beyond the evidence. The Endocrine Society's 2023 guidelines on menopausal management make no recommendation for routine urinary estrogen metabolite testing.

That honest picture does not make testing useless. It makes context essential.